Solid Biosciences Inc. (NASDAQ: SLDB) watched its shares get crushed on Thursday after the company announced some complications with the U.S. Food and Drug Administration (FDA). Specifically, the FDA notified the firm that its…
A new Merrill Lynch research report makes the case that four top biotech companies the firm covers have some powerful catalysts that could drive performance this year.
The SEC has finally charged Silicon Valley-based private company Theranos, along with its founder and CEO Elizabeth Holmes and former President Ramesh “Sunny” Balwani, with a massive fraud.
Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) shares made a solid gain on Tuesday after the company announced interim clinical data of BPX-501 in pediatric patients with acute myeloid leukemia (AML) and primary immunodeficiencies (PIDs).
Proteostasis Therapeutics saw its shares skyrocket going into Tuesday’s session following a pivotal decision from the FDA for the firm’s cystic fibrosis therapy.
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) saw its shares get absolutely crushed in Monday’s session following missed results in a late-stage study. Specifically, the company said that Sollpura did not meet the non-inferiority margin of…
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
These five top companies with different health care businesses all can provide nice exposure to the sector in growth portfolios. All are rated Buy at Jefferies and make sense now.
Vascular Biogenics watched its shares get absolutely crushed on Thursday after the firm reported top-line results for its late-stage trial in patients with recurrent glioblastoma.
Health insurer Cigna has agreed to acquire pharmacy benefits management firm Express Scripts for $67 billion, including debt. Is consolidation in the health care sector beginning to reach antitrust territory?